104 related articles for article (PubMed ID: 1389532)
1. Synergistic antiproliferative activity of tamoxifen and cisplatin on primary ovarian tumours.
Scambia G; Ranelletti FO; Benedetti Panici P; Piantelli M; De Vincenzo R; Bonanno G; Ferrandina G; Isola G; Mancuso S
Eur J Cancer; 1992; 28A(11):1885-9. PubMed ID: 1389532
[TBL] [Abstract][Full Text] [Related]
2. Synergistic antiproliferative activity of quercetin and cisplatin on ovarian cancer cell growth.
Scambia G; Ranelletti FO; Benedetti Panici P; Bonanno G; De Vincenzo R; Piantelli M; Mancuso S
Anticancer Drugs; 1990 Oct; 1(1):45-8. PubMed ID: 2131036
[TBL] [Abstract][Full Text] [Related]
3. Antiproliferative effect of silybin on gynaecological malignancies: synergism with cisplatin and doxorubicin.
Scambia G; De Vincenzo R; Ranelletti FO; Panici PB; Ferrandina G; D'Agostino G; Fattorossi A; Bombardelli E; Mancuso S
Eur J Cancer; 1996 May; 32A(5):877-82. PubMed ID: 9081370
[TBL] [Abstract][Full Text] [Related]
4. Oestrogen receptor expression and the effects of oestrogen and tamoxifen on the growth of human ovarian carcinoma cell lines.
Langdon SP; Hawkes MM; Lawrie SS; Hawkins RA; Tesdale AL; Crew AJ; Miller WR; Smyth JF
Br J Cancer; 1990 Aug; 62(2):213-6. PubMed ID: 2386737
[TBL] [Abstract][Full Text] [Related]
5. Effects of a new antioestrogen, idoxifene, on cisplatin- and doxorubicin-sensitive and -resistant human ovarian carcinoma cell lines.
Sharp SY; Rowlands MG; Jarman M; Kelland LR
Br J Cancer; 1994 Sep; 70(3):409-14. PubMed ID: 8080723
[TBL] [Abstract][Full Text] [Related]
6. Quercetin inhibits the growth of a multidrug-resistant estrogen-receptor-negative MCF-7 human breast-cancer cell line expressing type II estrogen-binding sites.
Scambia G; Ranelletti FO; Benedetti Panici P; Piantelli M; Bonanno G; De Vincenzo R; Ferrandina G; Pierelli L; Capelli A; Mancuso S
Cancer Chemother Pharmacol; 1991; 28(4):255-8. PubMed ID: 1879042
[TBL] [Abstract][Full Text] [Related]
7. Interaction with type II estrogen binding sites and antiproliferative activity of tamoxifen and quercetin in human non-small-cell lung cancer.
Caltagirone S; Ranelletti FO; Rinelli A; Maggiano N; Colasante A; Musiani P; Aiello FB; Piantelli M
Am J Respir Cell Mol Biol; 1997 Jul; 17(1):51-9. PubMed ID: 9224209
[TBL] [Abstract][Full Text] [Related]
8. Interaction of tamoxifen with cytosolic and nuclear type II estrogen binding sites (type II EBS).
Ferrandina G; Ranelletti FO; Scambia G; Benedetti Panici P; D'Agostino G; Piantelli M; Isola G; Mancuso S
Cancer Lett; 1995 Sep; 96(1):123-31. PubMed ID: 7553600
[TBL] [Abstract][Full Text] [Related]
9. Growth-inhibitory effect of tamoxifen and quercetin and presence of type II estrogen binding sites in human laryngeal cancer cell lines and primary laryngeal tumors.
Ferrandina G; Almadori G; Maggiano N; Lanza P; Ferlini C; Cattani P; Piantelli M; Scambia G; Ranelletti FO
Int J Cancer; 1998 Aug; 77(5):747-54. PubMed ID: 9688309
[TBL] [Abstract][Full Text] [Related]
10. Steroid receptors and response of ovarian cancer to cytostatic drugs in vitro.
Grönroos M; Kangas L; Mäenpää J; Vanharanta R; Paul R
Br J Obstet Gynaecol; 1984 May; 91(5):479-82. PubMed ID: 6232945
[TBL] [Abstract][Full Text] [Related]
11. Tamoxifen synergizes the antiproliferative effect of cisplatin in human ovarian cancer cells: enhancement of DNA platination as a possible mechanism.
Ercoli A; Scambia G; De Vincenzo R; Alimonti A; Petrucci F; Fattorossi A; Isola G; Benedetti Panici P; Caroli S; Mancuso S
Cancer Lett; 1996 Nov; 108(1):7-14. PubMed ID: 8950203
[TBL] [Abstract][Full Text] [Related]
12. Inhibitory effect of quercetin on OVCA 433 cells and presence of type II oestrogen binding sites in primary ovarian tumours and cultured cells.
Scambia G; Ranelletti FO; Panici PB; Piantelli M; Bonanno G; De Vincenzo R; Ferrandina G; Rumi C; Larocca LM; Mancuso S
Br J Cancer; 1990 Dec; 62(6):942-6. PubMed ID: 2257224
[TBL] [Abstract][Full Text] [Related]
13. Influence of tamoxifen on cisplatin-sensitivity and estrogen receptors expression in ovarian carcinoma cell lines.
Nowak-Markwitz E; Maciejczyk A; Pudełko M; Tserenchunt G; Balázs G; Spaczyński M; Zabel M; Dietel M; Lage H; Surowiak P
Ginekol Pol; 2010 Mar; 81(3):183-7. PubMed ID: 20486538
[TBL] [Abstract][Full Text] [Related]
14. Synergistic interaction between cisplatin and tamoxifen delays the emergence of cisplatin resistance in head and neck cancer cell lines.
Nakata B; Albright KD; Barton RM; Howell SB; Los G
Cancer Chemother Pharmacol; 1995; 35(6):511-8. PubMed ID: 7882460
[TBL] [Abstract][Full Text] [Related]
15. Type II oestrogen binding sites in acute lymphoid and myeloid leukaemias: growth inhibitory effect of oestrogen and flavonoids.
Larocca LM; Piantelli M; Leone G; Sica S; Teofili L; Panici PB; Scambia G; Mancuso S; Capelli A; Ranelletti FO
Br J Haematol; 1990 Aug; 75(4):489-95. PubMed ID: 2207000
[TBL] [Abstract][Full Text] [Related]
16. Tamoxifen modulation of cisplatin sensitivity in human malignant melanoma cells.
McClay EF; Albright KD; Jones JA; Christen RD; Howell SB
Cancer Res; 1993 Apr; 53(7):1571-6. PubMed ID: 8453625
[TBL] [Abstract][Full Text] [Related]
17. Effects of prolonged tamoxifen treatment on receptor expression and apoptosis of ovarian cancer cells.
Zhou R; Treeck O; Horn F; Ortmann O
Gynecol Oncol; 2005 Mar; 96(3):678-83. PubMed ID: 15721411
[TBL] [Abstract][Full Text] [Related]
18. Tamoxifen delays the development of resistance to cisplatin in human melanoma and ovarian cancer cell lines.
McClay EF; Albright KD; Jones JA; Christen RD; Howell SB
Br J Cancer; 1994 Sep; 70(3):449-52. PubMed ID: 8080729
[TBL] [Abstract][Full Text] [Related]
19. High progesterone receptor concentration in a variant of the ZR-75-1 human breast cancer cell line adapted to growth in oestrogen free conditions.
van den Berg HW; Martin J; Lynch M
Br J Cancer; 1990 Apr; 61(4):504-7. PubMed ID: 2139575
[TBL] [Abstract][Full Text] [Related]
20. Tamoxifen and quercetin interact with type II estrogen binding sites and inhibit the growth of human melanoma cells.
Piantelli M; Maggiano N; Ricci R; Larocca LM; Capelli A; Scambia G; Isola G; Natali PG; Ranelletti FO
J Invest Dermatol; 1995 Aug; 105(2):248-53. PubMed ID: 7636308
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
